| 2019-09-30 07:40:18|
07:40 09/30 09/30/19
Resverlogix says BETonMACE trial did not meet primary endpoint
Resverlogix announces that BETonMACE did not meet the primary endpoint - reduction in major adverse cardiovascular events, defined as cardiovascular death, non-fatal myocardial infarction and stroke - added to standard of care in high-risk patients with type 2 diabetes, recent acute coronary syndrome, and low HDL cholesterol. Apabetalone demonstrated tolerability and safety. Full study results will be presented during a late-breaking science session at AHA 2019. The primary results of the BETonMACE trial will be presented in the near future during the American Heart Association's Scientific Sessions 2019 held in Philadelphia, Pennsylvania, and submitted for peer review. The presentation is currently scheduled for approximately 11:42 am ET on November 16, 2019.